IMpassion130 Data Demonstrate Clinical Benefit for Immunotherapy in Metastatic TNBC
Leisha A. Emens, MD, PhD, professor of medicine at the UPMC Cancer Center, discusses how the data from the IMpassion130 trial have demonstrated benefit for immunotherapy in metastatic triple-negative breast cancer.
Leisha A. Emens, MD, PhD, professor of medicine at the UPMC Cancer Center, discusses how the data from the IMpassion130 trial have demonstrated benefit for immunotherapy in metastatic triple-negative breast cancer (mTNBC).
The IMpassion130 trial is a phase III study of atezolizumab (Tecentriq) plus nab-paclitaxel in patients with treatment-naïve, locally advanced or mTNBC. This is the first phase III trial to show clinical benefit in this patient population with use of an immunotherapy, Emens says.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
